Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2008

Charlesson Awarded Almost $1.6M from NIH to Advance AMD Mouse Model and Ocular Disease Drug Candidate

  • Charlesson received two SBIR grants from the NIH totaling close to $1.6 million to support development of a nanoparticle-formulated therapy for eye disease and a preclinical genetic animal model for age-related macular degeneration (AMD).

    Specifically, the firm obtained $210,357 to validate and commercialize its mouse model of AMD. Charlesson also received  over $1.38 million in a phase 2 SBIR grant to develop CLT-004 for treating AMD, diabetic retinopathy, and diabetic macular edema. These funds will be used to develop IND-enabling efficacy, safety, and toxicity profiles.

    CLT-004 is a small molecule that reduces retinal inflammation and vascular leakage, according to Charlesson. The firm is developing a sustained-release nanoparticle formulation of CLT-004 to treat blinding retinal disease.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »